Detection of clobazam and its metabolites in urine during poisoning using HPLC-QqQ-MS/MS

Abstract

BACKGROUND: Determining the incidence of acute and lethal poisoning with clobazam remains an urgent task of analytical toxicology. The medicinal substance clobazam belongs to the group of benzodiazepines, which is included in the list of psychoactive substances whose turnover is limited because of its high toxicity profile in overdose and abuse.

AIM: To propose a simple, reliable, and sensitive technique for the identification of clobazam and its metabolite in the urine by the modern high-performance liquid chromatography-tandem mass spectrometry (HPLC-QqQ-MS/MS).

MATERIALS AND METHODS: We have described a simple and sensitive HPLC-QqQ-MS/MS method for the qualitative determination of clobazam in the urine.

RESULTS: The retention time in the selected chromatography conditions for clobazam was 5.17 min, and its metabolite (norclobazam) in urine was 4.56 min. The base peaks for clobazam and norclobazam were 259 m/z and 245 m/z, respectively.

CONCLUSION: For the first time, this study provides a validated method of chemical-toxicological examination for poisoning with clobazam by HPLC-MS/MS, tested both on a model mixture and real biological matrix of the patient’s urine after taking clobazam. This technique can be a confirmatory research method in addition to the clinical picture in forensic medical examination.

Keywords

clobazam / high-performance liquid chromatography with tandem mass spectrometric detection / QqQ mass analyzer / HPLC-QqQ-MS/MS / detection / urine sample preparation

References

[1] Volkova AA, Orlova AM, Kalekin RA, Nevmyatova SR. Analysis of the possibility of conducting a forensic chemical study in case of Clobazam poisoning. Forensic Medical examination. 2022;65(1):35–40. (In Russ). doi: 10.17116/sudmed20226501135

[2] Волкова А.А., Орлова А.М., Калёкин Р.А., Невмятова С.Р. Анализ возможности проведения судебно-химического исследования при отравлении клобазамом // Судебно-медицинская экспертиза. 2022. Т. 65, № 1. С. 35–40. doi: 10.17116/sudmed20226501135

[3] Markin PA, Moskaleva NE, Appolonova SA, et al. Development of a thin-layer chromatography method for simultaneous determination of Clobazam and zaleplon in a mixture. In: Topical issues of forensic medicine and law. Collection of scientific and practical articles. Kazan; 2021. Р. 158–161. (In Russ).

[4] Маркин П.А., Москалева Н.Е., Апполонова С.А., и др. Разработка метода тонкослойной хроматографии для одновременного определения клобазама и залеплона в смеси // Актуальные вопросы судебной медицины и права: сборник научно-практических статей. Казань, 2021. С. 158–161.

[5] Orlova AM, Kalekin RA, Volkova AA, et al. Detection of Clobazam in urine by thin-layer chromatography. Bulletin Voronezh State University. 2021;(3):106–113. (In Russ).

[6] Орлова А.М., Калёкин Р.А., Волкова А.А., и др. Обнаружение клобазама в моче методом тонкослойной хроматографии // Вестник Воронежского государственного университета. 2021. № 3. С. 106–113.

[7] Gauthier AC, Mattson RH. Clobazam: A safe. Efficacious and newly rediscovered therapeutic for epilepsy. CNS Neurosci Ther. 2015;21(7):543–548. doi: 10.1111/cns.12399

[8] Gauthier A.C., Mattson R.H. Clobazam: A safe. Efficacious and newly rediscovered therapeutic for epilepsy // CNS Neurosci Ther. 2015. Vol. 21, N 7. Р. 543–548. doi: 10.1111/cns.12399

[9] Arya R, Giridharan N, Anand V, Garg SK. Clobazam monotherapy for focal or generalized seizures. Cochrane Database Syst Rev. 2018;2018(7):CD009258. doi: 10.1002/14651858.CD009258.pub3

[10] Arya R., Giridharan N., Anand V., Garg S.K. Clobazam monotherapy for focal or generalized seizures // Cochrane Database Syst Rev. 2018. Vol. 2018, N 7. Р. CD009258. doi: 10.1002/14651858.CD009258.pub3

[11] Tolbert D, Larsen FA. A comprehensive overview of the clinical pharmacokinetics of Clobazam. J Clin Pharmacol. 2019;59(1):7–19. doi: 10.1002/jcph.1313

[12] Tolbert D., Larsen F. A comprehensive overview of the clinical pharmacokinetics of Clobazam // J Clin Pharmacol. 2019. Vol. 59, N 1. Р. 7–19. doi: 10.1002/jcph.1313

[13] Kheireldin R. A case report of Clobazam toxicity related to cannabidiol and Clobazam drug-drug interaction. Translation University Toledo J Med Sci. 2019;(6):35–36. doi: 10.46570/utjms.vol6-2019-339

[14] Kheireldin R. A case report of Clobazam toxicity related to cannabidiol and Clobazam drug-drug interaction // Translation University Toledo J Med Sci. 2019. N 6. Р. 35–36. doi: 10.46570/utjms.vol6-2019-339

[15] Brigo F, Lattanzi S. Anticonvulsant agents: Benzodiazepines (Clobazam. Clonazepam. Diazepam. Lorazepam. Midazolam). In book: Riederer P., Laux G., Nagatsu T., et al., editors. NeuroPsychopharmacotherapy. Springer Nature Switzerland AG; 2020. Р. 1–8. doi: 10.1007/978-3-319-56015-1_440-1

[16] Brigo F., Lattanzi S. Anticonvulsant agents: Benzodiazepines (Clobazam. Clonazepam. Diazepam. Lorazepam. Midazolam) // Riederer P., Laux G., Nagatsu T., et al., editors. NeuroPsychopharmacotherapy. Springer Nature Switzerland AG, 2020. Р. 1–8. doi: 10.1007/978-3-319-56015-1_440-1

[17] Kheireldin R. A case report and literature review of Clobazam toxicity related to cbd and Clobazam drug-drug interaction. J Clin Med Res. 2019. doi: 10.37191/Mapsci-2582-4333-1(2)-012

[18] Kheireldin R. A case report and literature review of Clobazam toxicity related to CBD and Clobazam drug-drug interaction // J Clin Med Res. 2019. doi: 10.37191/Mapsci-2582-4333-1(2)-012

[19] Aung T. Rare but life-threatening aspiration pneumonia related to initiation of Clobazam therapy. Epilepsy Behavior Rep. 2020;14:100406. doi: 10.1016/j.ebr.2020.100406

[20] Aung T. Rare but life-threatening aspiration pneumonia related to initiation of Clobazam therapy // Epilepsy Behavior Rep. 2020. N 14. Р. 100406. doi: 10.1016/j.ebr.2020.100406

[21] Huddart R, Leeder JS, Altman RB, Klein TE. Pharm GKB summary: Clobazam pathway. Pharmacokinetics. Pharmacogenet Genomics. 2018;28(4):110–115. doi: 10.1097/FPC.0000000000000327

[22] Huddart R., Leeder J.S., Altman R.B., Klein T.E. Pharm GKB summary: Clobazam pathway. Pharmacokinetics // Pharmacogenet Genomics. 2018. Vol. 28, N 4. Р. 110–115. doi: 10.1097/FPC.0000000000000327

[23] Hammer H, Ebert B, Jensen HS, Jensen AA. Functional characterization of the 1.5-benzodiazepine Clobazam and its major active metabolite N-desmethylclobazam at human GABAA receptors expressed in xenopus laevis oocytes. PLoS One. 2015;10(3):e0120239. doi: 10.1371/journal.pone.0120239

[24] Hammer H., Ebert B., Jensen H.S., Jensen A.A. Functional characterization of the 1.5-benzodiazepine Clobazam and its major active metabolite N-desmethylclobazam at human GABAA receptors expressed in xenopus laevis oocytes // PLoS One. 2015. Vol. 10, N 3. Р. e0120239. doi: 10.1371/journal.pone.0120239

[25] Souri E, Farahani AD, Ahmadkhaniha R, Amini M. A stability indicating HPLC method for the determination of Clobazam and its basic degradation product characterization. Daru. 2014;22(1):49. doi: 10.1186/2008-2231-22-49

[26] Souri E., Farahani A.D., Ahmadkhaniha R., Amini M. A stability indicating HPLC method for the determination of Clobazam and its basic degradation product characterization // Daru. 2014. Vol. 22, N 1. Р. 49. doi: 10.1186/2008-2231-22-49

[27] Jensen HS, Nichol K, Lee D, Ebert B. Clobazam and its active metabolite N-desmethylclobazam display significantly greater affinities for α2- versus α1-GABAA-receptor complexes. PLoS One. 2014;9(2):e88456. doi: 10.1371/journal.pone.0088456

[28] Jensen H.S., Nichol K., Lee D., Ebert B. Clobazam and its active metabolite N-desmethylclobazam display significantly greater affinities for α2- versus α1-GABAA-receptor complexes // PLoS One. 2014. Vol. 9, N 2. Р. e88456. doi: 10.1371/journal.pone.0088456

[29] Bajaja AO, Ly D, Johnson-Davisab KL. Retrospective analysis of metabolite patterns of Clobazam and N-desmethylclobazam in human plasma by LC-MS/MS. J Mass Spectrom Adv Clin Lab. 2022;(24):100–106. doi: 10.1016/j.jmsacl.2022.04.005

[30] Bajaja A.O., Ly D., Johnson-Davisab K.L. Retrospective analysis of metabolite patterns of Clobazam and N-desmethylclobazam in human plasma by LC-MS/MS // J Mass Spectrom Adv Clin Lab. 2022. N 24. Р. 100–106. doi: 10.1016/j.jmsacl.2022.04.005

[31] Laloup M, Fernandez MR, De Boeck G, et al. Validation of a liquid chromatography-tandem mass spectrometry method for the simultaneous determination of 26 benzodiazepines and metabolites, zolpidem and zopiclone, in blood, urine, and hair. J Anal Toxicol. 2005;29(7):616–626. doi: 10.1093/jat/29.7.616

[32] Laloup M., Fernandez M.R., De Boeck G., et al. Validation of a liquid chromatography-tandem mass spectrometry method for the simultaneous determination of 26 benzodiazepines and metabolites, zolpidem and zopiclone, in blood, urine, and hair // J Anal Toxicol. 2005. Vol. 29, N 7. Р. 616–626. doi: 10.1093/jat/29.7.616

RIGHTS & PERMISSIONS

Eco-Vector